Gene therapy companies have an ethical obligation to develop expanded access policies

Lisa Kearns, Carolyn Riley Chapman, Kenneth I. Moch, Arthur L. Caplan, Tom Watson, Andrew McFadyen, Pat Furlong, Alison Bateman-House

Molecular Therapy · 2021 · 17 citations · 3 references

DOIFull text

Open access

Concepts

Abstract

In the US, gene therapy companies, as with all biopharmaceutical companies, are not required by law or regulation to provide their investigational products to patients via non-trial preapproval (expanded) access. However, we believe that gene therapy companies, in particular, have a moral obligation to develop policies regarding such access, historically known as “compassionate use.” Gene therapies are predominantly intended for patients with serious or life-threatening rare diseases for which there are limited treatments;1 this should compel companies to develop product-specific non-trial preapproval access policies.

References

3